Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) | terminated | Phase 1 | 33 | Korea Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 |
| clinicaltrials |
| NCT03130712 | A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) | unknown | Phase 1 / Phase 2 | 10 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Apr 26, 2017 | clinicaltrials |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT03124498 | A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA | unknown | Phase 1 / Phase 2 | 55 | Chuan An Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 21, 2017 | clinicaltrials |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02174887 | Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer(MOAnab1) | completed | Phase 1 | 19 | Institut Paoli-CalmettesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients | terminated | Phase 1 / Phase 2 | 6 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | terminated | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT03084380 | Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 4 | Mar 6, 2017 | clinicaltrials |
| NCT01656265 | Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 24 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01668134 | Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma | completed | Phase 1 | 28 | Washington University School of MedicineOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00516165 | RAD001 in Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 / Phase 2 | 0 | Philipps University MarburgOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT02959151 | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy | unknown | Phase 1 / Phase 2 | 20 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT01308723 | A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01897038 | A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT00846131 | Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma | completed | Phase 1 | 24 | Northwestern UniversityOTHER | 1 | Sep 15, 2016 | clinicaltrials |
| NCT02150135 | Effect of Oncothermia on Improvement of Quality of Life in Unresectable Pancreatic Cancer Patients | completed | Phase 1 | 10 | Seoul National University HospitalOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02882659 | Dendritic Killer Cell-based Immunotherapy for Solid Tumors | unknown | Phase 1 | 18 | FullHope Biomedical Co., Ltd.INDUSTRY | 0 | Aug 30, 2016 | clinicaltrials |
| NCT01733004 | A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Merrimack PharmaceuticalsINDUSTRY | 2 | Aug 4, 2016 | clinicaltrials |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Stanford UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT02399735 | Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation | unknown | Phase 1 | 18 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT01242605 | ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer(ABC-04) | completed | Phase 1 | 13 | University College, LondonOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT02772029 | A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT01008566 | Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | May 12, 2016 | clinicaltrials |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 3 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | unknown | Phase 1 | 112 | e-Therapeutics PLCINDUSTRY | 4 | Apr 6, 2016 | clinicaltrials |
| NCT02727309 | A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients | unknown | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02586285 | Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma | unknown | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02587884 | Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH | unknown | Phase 1 | 180 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT02724332 | Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC | completed | Phase 1 | 300 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01692704 | Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy | completed | Phase 1 / Phase 2 | 12 | University of ZurichOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01446458 | Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Mar 22, 2016 | clinicaltrials |
| NCT02715362 | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC(GPC3-CART) | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 22, 2016 | clinicaltrials |
| NCT01274455 | Gene Therapy of Pancreatic Ductal Adenocarcinoma(TherGAP) | completed | Phase 1 | 22 | University Hospital, ToulouseOTHER | 1 | Mar 14, 2016 | clinicaltrials |
| NCT02210182 | A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma | completed | Phase 1 | 29 | Oncozyme Pharma Inc.INDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01147380 | Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation(MIAMINK) | completed | Phase 1 | 18 | Seigo NishidaOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02101593 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
Data updated 23 days agoSource updated May 9, 2017source: clinicaltrials